I know I’m supposed to be enamored with biotech right now. After all, old-school pharmaceutical companies are wildly desperate for new great products, and only biotech can supply them. That’s why Roche bought the rest of Genentech, and why Gilead (GILD) acquired CV Therapeutics (CVTX), right? Surely this must be the beginning of a wave of biotech acquisitions and mergers that are going to make current biotech owners a small fortune when their particular stock gets snatched up at a premium, right?
Funny thing though…. the biotech indices are still headed lower, even while the broad market is rising. What gives?
Here’s what gives…there’s more hype than hope here. After Merck (MRK) and Schering-Plough (SGP) teamed up, and after Pfizer (PFE) joined forces with Wyeth (WYE) - plus the Gilead/CV Therapeutics deal - not only have we NOT seen a firestorm of M&A, we’ve actually seen none at all… at least none that I can think of.
I know the entire pharma sector (biotech in particular) has been put on a pedestal of late, as some of these stocks were the only thing that did reasonably well in a very nasty 2008. In fact, as of early March, on a proportional basis, there were more ‘buy’ ratings on pharma stocks than for any other industry. And brother, the market is singing pharma’s praises right now, potential or real. Most of this stemmed from M&A hopes, it seems.
Call me contrarian, but doesn’t it feel kind of uncomfortable that everyone else seems to have so much confidence in the group right now? I can’t shake off an old Wall Street adage I’ve personally known to be true way too often…. “When everyone else wants it, sell it. When nobody else wants it, buy it.”
Here’s the even-bigger irony - investors who have placed bets on strong performance from biotech stocks have not only lost ground, they’ve underperformed the overall market. Year-to-date, the average biotech stock is down 16%, while the market is only down about 8%. This week, the average biotech stock is down 8%, while the market is up about 2%.
Correct me if I’m wrong, but aren’t “sure things” (like biotech is right now) supposed to, you know… go up?
No, I think we’ve all been duped following 2008’s plethora of pharma M&A, and then this March’s flurry of it from some of the biggest names in the biz. The buzz in March was that the Merck, Pfizer, Gilead, Roche, Genentech, Wyeth, and Schering-Plough deals were the sign of the beginning of M&A madness. However, I think it actually may have been the culmination and finalization of a trend rather than a beginning. Check this out…
Prominent mergers and acquisitions attorney Adam Berger recently said 2008 was the biggest biopharma M&A year in the last ten. And, that’s true…. in calendar 2008 there were 150 biotech deals done, worth a combined $97 billion. Despite a few huge mergers in March, 2009’s biotech M&A rate is nowhere close to that pace.
In other words, 2008’s mergers are not evidence of a trend, but rather, 2009’s mega-deals could be a hint of a blowoff top and exhaustion of potential mergers.
Even if we do see a few more deals flow through in 2009, a recent story by IBD columnist Peter Benesh illustrates more risk than reward if you’re fishing for an acquisition.
In the column, Benesh states Peter Becker (former CEO of VioQuest and Cytogen) believes more than 100 biotech companies could be out of money by the middle of the year. One of the cash-rich mega-companies could wipe those woes away, but I seriously doubt the majority of them will be salvaged by big pharma; big pharma’s got enough to take care of already. Hopefully you’re not speculating on one of those 100+ stocks that won’t be bought out.
On that note, I want to stress something else that suggests to me that major drug-makers aren’t nearly as interested in small biotechs as we want to think they are….
Big pharma doesn’t need to finance the acquisition of anything - they can pay cash for most of the second tier companies in the biotech group, meaning if an acquisition was going to happen at all, it would have happened by now. I suspect that’s why we saw so much M&A in 2008 (much of which was off the radar)…. because stocks were so cheap. Now, in the shadow of what looks to be a real shot at economic recovery, stock prices are rising again. That cheap acquisition window is closing.
I’m going to close with that thought, as the message has been delivered adequately. However, I urge you to come back to the blog and the newsletter next week, as I have at least two more columns I’ll need to write - about specific companies and market caps - that further support my minority thesis about biotech stocks’ foreseeable futures.
Stop following the crowd, and start leading it. Stop listening to TV’s talking heads regurgitate press releases, and start getting some real, money-making perspective like this. Sign up for the Small Cap Network newsletter, and we’ll tell you when it’s the right time or wrong time to buy biotech.